摘要
目的:通过阿德福韦酯联合安络化纤丸治疗慢性乙型肝炎及其引起的肝硬化,探寻治疗肝纤维化、缓解肝硬化、降低肝硬化发生率的有效方法。方法:76例慢性乙型肝炎或乙型肝炎肝硬化患者,服用阿德福韦酯及安络化纤丸,观察肝功能、病毒学指标、肝纤4项、肝脏B超及组织学的变化。对照组69例,仅予护肝治疗,无抗病毒及抗肝纤维化治疗。结果:治疗组患者经3个月治疗,肝功能大部分复常;6个月,HBVDNA阴转或处于低水平,肝纤4项大部分复常;12个月,部分患者HBeAg阴转,肝穿活检组织学改善;18个月肝硬化患者肝脏B超明显改善。同期对照组患者仍反复肝功能异常,肝纤维化指标大部分无改善。结论:阿德福韦酯联合安络化纤丸对肝纤维化具有明显的疗效。
Objective： To explore an effective method of curing liver fibrosis, improving liver cirrhosis and decreasing the rate of liver cirrhosis by the therapy of adefovir dipivoxil in combination with Anluo Huaxian Wan on patients with chronic hepatitis B or liver cirrhosis. Methods： Seventy-six patients with chronic hepatitis B or liver cirrhosis were given adefovir dipivoxil and Anluo Huaxian Wan. The changes of liver function, viral load, liver fibrosis markers, ultrasound examination and histology were observed. The control group including 69 similar patients was only given protecting liver function therapy without anti-virus and anti-liver fibrosis treatment. Results： The liver function of treatment group had significant improvement after 3 months. HBV DNA was negative conversion or low level and liver fibrosis markers restored nomal mostly at 6 months. Part of the patients acquired HBeAg negative conversion and improvement of liver histology at 12 months. The examination of liver ultrasound revealed significant improvement of liver cirrhosis at 18 months, though the patients of control group still had abnomal liver function repeatedly and most of the liver fibrosis markers had no improvement, Conclusion： Adefovir dipivoxil in combination with Anluo Huaxian Wan had significant effect in treating liver fibrosis.
出处
《中西医结合肝病杂志》
CAS
2008年第2期80-82,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
